0 411

Cited 3 times in

Efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver disease: A multicentre, double-blind, randomized, comparative trial

DC Field Value Language
dc.contributor.author이병완-
dc.date.accessioned2022-05-09T17:01:14Z-
dc.date.available2022-05-09T17:01:14Z-
dc.date.issued2022-04-
dc.identifier.issn1462-8902-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/188336-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherWiley-Blackwell-
dc.relation.isPartOfDIABETES OBESITY & METABOLISM-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHDiabetes Mellitus, Type 2* / complications-
dc.subject.MESHDiabetes Mellitus, Type 2* / drug therapy-
dc.subject.MESHDipeptidyl-Peptidase IV Inhibitors* / adverse effects-
dc.subject.MESHDouble-Blind Method-
dc.subject.MESHHumans-
dc.subject.MESHLiver-
dc.subject.MESHNon-alcoholic Fatty Liver Disease* / complications-
dc.subject.MESHNon-alcoholic Fatty Liver Disease* / drug therapy-
dc.subject.MESHPiperazines-
dc.titleEfficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver disease: A multicentre, double-blind, randomized, comparative trial-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorEugene Han-
dc.contributor.googleauthorJi Hye Huh-
dc.contributor.googleauthorEun Y Lee-
dc.contributor.googleauthorJi C Bae-
dc.contributor.googleauthorSung W Chun-
dc.contributor.googleauthorSung H Yu-
dc.contributor.googleauthorSoo H Kwak-
dc.contributor.googleauthorKyong S Park-
dc.contributor.googleauthorByung-Wan Lee-
dc.identifier.doi10.1111/dom.14623-
dc.contributor.localIdA02796-
dc.relation.journalcodeJ00722-
dc.identifier.eissn1463-1326-
dc.identifier.pmid34918436-
dc.identifier.urlhttps://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14623-
dc.subject.keyworddipeptidyl peptidase-4 inhibitor-
dc.subject.keywordevogliptin-
dc.subject.keywordmagnetic resonance imaging-derived proton density fat fraction-
dc.subject.keywordnon-alcoholic fatty liver disease-
dc.subject.keywordpioglitazone-
dc.subject.keywordtype 2 diabetes-
dc.contributor.alternativeNameLee, Byung Wan-
dc.contributor.affiliatedAuthor이병완-
dc.citation.volume24-
dc.citation.number4-
dc.citation.startPage752-
dc.citation.endPage756-
dc.identifier.bibliographicCitationDIABETES OBESITY & METABOLISM, Vol.24(4) : 752-756, 2022-04-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.